Filler-Induced Lymphatic Compromise: In Silico Modelling of Facial Safety Thresholds and Injection Techniques

Soft tissue fillers are central to facial rejuvenation, but their impact on lymphatic drainage is poorly quantified. Lymphatic vessels operate at very low pressures and collapse with modest external load. Persistent oedema in regions such as the tear trough and malar area suggests filler-lymphatic interactions drive complications.

A multiscale finite element model was built in the AesthetiSIM™ platform to simulate filler-tissue-lymphatic interactions. A virtual cohort of 10,000 anatomically varied patients was generated from MRI, cadaveric, and lymphangiographic data. Seven facial regions (tear trough, malar, nasolabial fold, lips, chin, jawline, and temple) were represented as layered tissue blocks with embedded lymphatic collectors. Hyaluronic acid (HA) was modelled as a hygroscopic hydrogel and calcium hydroxylapatite (CaHA) as a stiffer, non-swelling suspension. Outputs included external pressure on lymphatic collectors, lumen collapse, interstitial flux, and a 24 h oedema index. Statistical analysis used hierarchical logistic regression, functional principal component analysis, copula modelling, and global Sobol sensitivity decomposition.

Three reproducible volume thresholds emerged across the population: (1) lymphatic flow perturbation above 0.20 mL, (2) structural compromise with 25-30% lumen narrowing above 0.40 mL, and (3) critical obstruction near 0.93 mL. Tear trough and malar regions were more vulnerable, with HA obstruction at 0.54 mL and CaHA at 0.41-0.43 mL. CaHA produced earlier, sharper pressure peaks due to higher stiffness, whereas HA caused delayed, swelling-driven collapse. Posture and injection depth altered risk: dependent positioning increased early collapse in chin and jawline, and supraperiosteal placement concentrated stress on superficial collectors. Long threading tracks reduced peak pressure but widened areas of moderate compression.

Filler-induced lymphatic compromise occurs at volumes far below traditional "safe" doses. No injected volume is physiologically inert: even 0.2 mL measurably perturbs drainage. Safety requires region-specific dosing, avoidance of bolus injections in high-risk sites, and preference for distributed techniques to reduce lymphatic compression.

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .